$TECX
Tectonic Therapeutic, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019030417 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q4 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.350M $3.870M $2.140M
YoY Change 103.27% 298.97% 224.24%
% of Gross Profit
Research & Development $12.27M $12.81M $7.407M
YoY Change 65.61% 97.99% 293.78%
% of Gross Profit
Depreciation & Amortization $200.0K $180.0K $50.00K
YoY Change 300.0% 800.0% 150.0%
% of Gross Profit
Operating Expenses $16.61M $16.68M $9.547M
YoY Change 74.0% 124.5% 275.57%
Operating Profit -$16.61M -$9.547M
YoY Change 74.0% 275.57%
Interest Expense $560.0K $660.0K -$810.0K
YoY Change -169.14% -512.5% -8200.0%
% of Operating Profit
Other Income/Expense, Net $557.0K $0.00 -$960.0K
YoY Change -158.02% -100.0% -12100.0%
Pretax Income -$16.06M -$16.02M -$10.51M
YoY Change 52.81% 110.79% 315.42%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.06M -$16.02M -$10.51M
YoY Change 52.8% 110.79% 314.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$667.8K -$668.9K -$439.0K
COMMON SHARES
Basic Shares Outstanding 24.15M shares 23.96M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q4 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.30M $126.3M $155.0M
YoY Change -41.74%
Cash & Equivalents $90.35M $126.3M $155.0M
Short-Term Investments
Other Short-Term Assets $329.0K $795.0K $294.0K
YoY Change 11.9% 1225.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $98.19M $130.0M $156.1M
YoY Change -37.12% 1961.19%
LONG-TERM ASSETS
Property, Plant & Equipment $2.741M $2.634M $2.050M
YoY Change 33.71% 654.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.060M $825.0K $533.0K
YoY Change 98.87% 126.03%
Total Long-Term Assets $3.801M $3.459M $2.583M
YoY Change 47.15% 384.45%
TOTAL ASSETS
Total Short-Term Assets $98.19M $130.0M $156.1M
Total Long-Term Assets $3.801M $3.459M $2.583M
Total Assets $102.0M $133.5M $158.7M
YoY Change -35.75% 1800.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.572M $2.784M $4.193M
YoY Change -38.66% 428.27%
Accrued Expenses $6.193M $7.822M $5.438M
YoY Change 13.88% 272.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.765M $10.61M $9.631M
YoY Change -8.99% 304.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change -25.0% 40.0%
Total Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change -25.0% 40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.765M $10.61M $9.631M
Total Long-Term Liabilities $600.0K $700.0K $800.0K
Total Liabilities $9.355M $11.30M $10.41M
YoY Change -10.15% 208.86%
SHAREHOLDERS EQUITY
Retained Earnings -$104.9M -$71.74M -$44.13M
YoY Change 137.72% 205.61%
Common Stock $197.5M $193.9M $192.4M
YoY Change 2.64% 57104.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $92.63M $122.2M $148.3M
YoY Change
Total Liabilities & Shareholders Equity $102.0M $133.5M $158.7M
YoY Change -35.75% 1800.87%

Cashflow Statement

Concept 2019 Q2 2018 Q4 2018 Q2
OPERATING ACTIVITIES
Net Income -$16.06M -$16.02M -$10.51M
YoY Change 52.8% 110.79% 314.64%
Depreciation, Depletion And Amortization $200.0K $180.0K $50.00K
YoY Change 300.0% 800.0% 150.0%
Cash From Operating Activities -$17.96M -$11.44M -$8.250M
YoY Change 117.7% 29.71% 236.73%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$490.0K -$160.0K
YoY Change 150.0% 512.5%
Acquisitions
YoY Change
Other Investing Activities $0.00 $20.00K
YoY Change -100.0%
Cash From Investing Activities -$400.0K -$230.0K -$140.0K
YoY Change 185.71% 187.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $104.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.0K -140.0K 105.5M
YoY Change -99.77% -101.0% -211040.0%
NET CHANGE
Cash From Operating Activities -17.96M -11.44M -8.250M
Cash From Investing Activities -400.0K -230.0K -140.0K
Cash From Financing Activities 240.0K -140.0K 105.5M
Net Change In Cash -18.12M -11.81M 97.08M
YoY Change -118.67% -332.94% -3983.2%
FREE CASH FLOW
Cash From Operating Activities -$17.96M -$11.44M -$8.250M
Capital Expenditures -$400.0K -$490.0K -$160.0K
Free Cash Flow -$17.56M -$10.95M -$8.090M
YoY Change 117.06% 25.29% 230.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001681087
dei Local Phone Number
LocalPhoneNumber
914-8420
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei City Area Code
CityAreaCode
617
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 201
dei Entity Registrant Name
EntityRegistrantName
AVROBIO, INC.
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity File Number
EntityFileNumber
001-38537
us-gaap Investment Income Interest
InvestmentIncomeInterest
392000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90348000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
126302000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7840000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3718000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
98188000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
130020000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2741000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2634000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1060000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
825000
CY2019Q2 us-gaap Assets
Assets
101989000
CY2018Q4 us-gaap Assets
Assets
133479000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2572000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2784000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6193000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7822000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8765000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10606000
CY2019Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
590000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
689000
CY2019Q2 us-gaap Liabilities
Liabilities
9355000
CY2018Q4 us-gaap Liabilities
Liabilities
11295000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197529000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193921000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104897000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71739000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
92634000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
122184000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101989000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133479000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.98
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
810710585
dei Entity Address Address Line1
EntityAddressAddressLine1
One Kendall Square
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109000
dei Document Type
DocumentType
10-Q
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24713000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13054000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2140000
us-gaap Net Income Loss
NetIncomeLoss
-18749000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16055000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1414000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-10507000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
106788000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.16
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3529269
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23985717
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1663000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.38
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16612000
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 300
us-gaap Operating Expenses
OperatingExpenses
34312000
us-gaap Operating Expenses
OperatingExpenses
17335000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9547000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17335000
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
234000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1222000
CY2019Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2018Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2000
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q2 avro Issuance Of Common Stock Net Of Issuance Costs
IssuanceOfCommonStockNetOfIssuanceCosts
10487000
us-gaap Profit Loss
ProfitLoss
-33158000
us-gaap Profit Loss
ProfitLoss
-18749000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
390000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5963000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
197000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
148318000
CY2018Q1 avro Temporary Equity Issuance Of Redeemable Convertible Preferred Stock Net Of Issuance Costs
TemporaryEquityIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts
2243000
us-gaap Share Based Compensation
ShareBasedCompensation
3118000
us-gaap Share Based Compensation
ShareBasedCompensation
566000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24187052
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23959903
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24095287
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23806628
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12267000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7407000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4345000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9599000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4281000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
16612000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
9547000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34312000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
565000
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
150000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
162000
CY2018Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1042000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1629000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
557000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-960000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16055000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10507000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
2243000
CY2019Q2 avro Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-16055000
CY2018Q2 avro Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-10507000
avro Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-33158000
avro Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-20992000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2930358
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1455000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
252000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17103000
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-23135000
CY2018Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2243000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8242000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-33511000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
104182000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
457000
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2018Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
87500000
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
22000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
235000
avro Deferred Rent Expense
DeferredRentExpense
-81000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
68000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1154000
us-gaap Net Income Loss
NetIncomeLoss
-33158000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33158000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18749000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24046262
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3948622
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2926138
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
768000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
57000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
300000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26000
avro Deferred Rent Expense
DeferredRentExpense
-23000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4121000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3029000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1820000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-98000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35703000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14229000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-24000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
741000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
424000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-741000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-400000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
58258000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
490000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
105423000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
490000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163681000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35954000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
149052000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126794000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90840000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155015000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
756000
avro Property And Equipment Held For Sale
PropertyAndEquipmentHeldForSale
19000
avro Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
180000
avro Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
1241000
avro Purchases Of Property And Equipment Paid For By Landlord
PurchasesOfPropertyAndEquipmentPaidForByLandlord
842000
avro Accretion Of Issuance Costs Related To Redeemable Convertible Preferred Stock
AccretionOfIssuanceCostsRelatedToRedeemableConvertiblePreferredStock
2240000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154991000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
492000
CY2018Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
24000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. (the &#8220;Company&#8221; or &#8220;AVROBIO&#8221;) is a clinical stage gene therapy company focused on developing potentially curative <font style="font-style:italic;">ex vivo</font> lentiviral gene therapies to treat rare diseases following a single dose. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;20, 2018, the Company&#8217;s registration statement on&#160;Form&#160;S-1&#160;relating to its initial public offering (&#8220;IPO&#8221;) was declared effective by the SEC. The IPO closed on June&#160;25, 2018 and the Company issued and sold 5,247,958 common shares at a public offering price of $19.00 per share for net proceeds of $90,103 after deducting underwriting discounts and commissions of $6,980 and other offering expenses of approximately $2,628. Simultaneously, on June&#160;25, 2018, the Company issued and sold 787,193 additional common shares, pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, for net proceeds of $13,910 after deducting underwriting discounts and commissions of $1,047. Thus, the aggregate net proceeds to the Company from the IPO, after deducting underwriting discounts and commissions and other offering costs, were $104,013. Upon the closing of the IPO, all series Seed redeemable convertible preferred stock (the &#8220;Series Seed Preferred Stock&#8221;), series&#160;A redeemable convertible preferred stock (the &#8220;Series&#160;A Preferred Stock&#8221;) and series&#160;B redeemable convertible preferred stock (the &#8220;Series&#160;B Preferred Stock&#8221;), (the Series Seed Preferred Stock, the Series&#160;A Preferred Stock and the Series&#160;B Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221;) then outstanding converted into an aggregate of 15,320,213 shares of common stock. In July 2019, the Company closed an underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $18.50 per share, which included 975,000 shares of the Company&#8217;s common stock resulting from the full exercise of the underwriters&#8217; option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The net proceeds to the Company from this offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, were approximately $129,500.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through June 30, 2019, the Company has funded its operations primarily with proceeds from the sale of the Preferred Stock and common stock through the Company&#8217;s IPO. The Company has incurred recurring losses since its inception, including net losses of $33,158 and $18,749 for the six months ended June 30, 2019 and 2018, respectively. In addition, as of June 30, 2019, the Company had an accumulated deficit of $104,897. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the date of issuance of the financial statements contained in this&#160;Form&#160;10-Q. However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. </p>
CY2019Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
163000
CY2018Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
220000
CY2019Q2 us-gaap Prepaid Rent
PrepaidRent
83000
CY2018Q4 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
981000
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
104013000
CY2018Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
15320213
CY2019Q2 avro Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
0
CY2019Q2 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
1549000
CY2018Q4 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
1325000
CY2019Q2 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
4090000
CY2019Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1626000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
316000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, stock-based compensation expense, the valuation of equity and derivative instruments and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates. </p>
CY2019Q2 us-gaap Security Deposit
SecurityDeposit
209000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.63
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
153275
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.42
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
29000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
26000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2300
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
61510
avro Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
94065
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.65
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1663000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
457000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3118000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
566000
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
21334000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M20D
CY2018Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-01-31
CY2018Q1 avro Operating Lease Annual Increase In Rental Percentage
OperatingLeaseAnnualIncreaseInRentalPercentage
0.03
CY2018Q1 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
842000
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
81000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
329000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
795000
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3515000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3018000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
774000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
384000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
45000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
390000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
66000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2118000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2616000
CY2019Q2 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3253000
CY2018Q4 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3969000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
401000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
320000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
421000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
917000
CY2019Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
63491857
CY2019Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q2 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2018Q4 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2019Q2 avro Undesignated Preferred Stock Outstanding
UndesignatedPreferredStockOutstanding
0
CY2018Q4 avro Undesignated Preferred Stock Outstanding
UndesignatedPreferredStockOutstanding
0
us-gaap Dividends Cash
DividendsCash
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0254
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0273
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8086
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8386
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2164100
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1094879
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
227149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
74373
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2957457
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
669887
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2957457
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.15
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.41
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.59
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.41
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23083000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18956000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9224000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
18956000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.37

Files In Submission

Name View Source Status
0001564590-19-030417-index-headers.html Edgar Link pending
0001564590-19-030417-index.html Edgar Link pending
0001564590-19-030417.txt Edgar Link pending
0001564590-19-030417-xbrl.zip Edgar Link pending
avro-10q_20190630.htm Edgar Link pending
avro-20190630.xml Edgar Link completed
avro-20190630.xsd Edgar Link pending
avro-20190630_cal.xml Edgar Link unprocessable
avro-20190630_def.xml Edgar Link unprocessable
avro-20190630_lab.xml Edgar Link unprocessable
avro-20190630_pre.xml Edgar Link unprocessable
avro-ex311_7.htm Edgar Link pending
avro-ex312_8.htm Edgar Link pending
avro-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gxhimyqbjfge000001.jpg Edgar Link pending
gxhimyqbjfge000002.jpg Edgar Link pending
gxhimyqbjfge000003.jpg Edgar Link pending
gxhimyqbjfge000004.jpg Edgar Link pending
gxhimyqbjfge000005.jpg Edgar Link pending
gxhimyqbjfge000006.jpg Edgar Link pending
gxhimyqbjfge000007.jpg Edgar Link pending
gxhimyqbjfge000008.jpg Edgar Link pending
gxhimyqbjfge000009.jpg Edgar Link pending
gxhimyqbjfge000010.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending